{"id":185756,"date":"2026-02-09T08:07:00","date_gmt":"2026-02-09T13:07:00","guid":{"rendered":"https:\/\/testing.news-you-need.com\/index.php\/2026\/02\/09\/iambic-could-earn-almost-2-billion-in-new-takeda-deal\/"},"modified":"2026-02-09T08:30:14","modified_gmt":"2026-02-09T13:30:14","slug":"iambic-could-earn-almost-2-billion-in-new-takeda-deal","status":"publish","type":"post","link":"https:\/\/testing.news-you-need.com\/index.php\/2026\/02\/09\/iambic-could-earn-almost-2-billion-in-new-takeda-deal\/","title":{"rendered":"Iambic could earn almost $2 billion in new Takeda deal"},"content":{"rendered":"<p><a href=\"https:\/\/cen.acs.org\/business\/investment\/Iambic-earn-almost-2-billion\/104\/web\/2026\/02\">Iambic could earn almost $2 billion in new Takeda deal<\/a><\/p>\n<p><a href=\"https:\/\/cen.acs.org\/business\/investment\/Iambic-earn-almost-2-billion\/104\/web\/2026\/02\">https:\/\/cen.acs.org\/business\/investment\/Iambic-earn-almost-2-billion\/104\/web\/2026\/02<\/a><\/p>\n<p>Publish Date: <a href=\"publish_date]\">2026-02-09 08:07:00<\/a><\/p>\n<p>Source Domain: <a href=\"cen.acs.org\">cen.acs.org<\/a><\/p>\n<ul>\n<li>\n<p>Iambic Therapeutics, a startup blending physics and AI for drug discovery, has secured a major collaboration with Japan&#8217;s Takeda Pharmaceutical.<\/p>\n<\/li>\n<li>\n<p>Under the partnership, Takeda will use Iambic&#8217;s AI models to develop small-molecule drugs for oncology, inflammation, and gastrointestinal diseases; potential revenues could exceed $1.7 billion over time with additional royalties on sales.<\/p>\n<\/li>\n<li>\n<p>Iambic&#8217;s &#8220;physics-informed&#8221; AI platform, NeuralPLexer, combines protein language models with a graph-based molecular encoder to enhance the predictability and accuracy of drug discovery.<\/p>\n<\/li>\n<li>\n<p>CEO Tom Miller highlights that Iambic\u2019s AI models are uniquely informed by physics, making them more efficient and accurate compared to competitors. <\/p>\n<\/li>\n<li>\n<p>Iambic&#8217;s AI models consistently refine accuracy through continuous learning from its lab data, completing a molecule-to-validation cycle within ten days.<\/p>\n<\/li>\n<li>\n<p>Miller, a former Caltech chemistry professor, cofounded Iambic in 2020 to bridge research into patient-ready medicines; the company has raised over $300 million and is backed by notable investors.<\/p>\n<\/li>\n<li>\n<p>Takeda joins other partners including Lundbeck and Revolution Medicines in leveraging Iambic&#8217;s AI platforms for drug development, each partnership reflecting varied focuses from technology deployment to molecule co-development.<\/p>\n<\/li>\n<\/ul>\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Iambic could earn almost $2 billion in new Takeda deal https:\/\/cen.acs.org\/business\/investment\/Iambic-earn-almost-2-billion\/104\/web\/2026\/02 Publish Date: 2026-02-09 08:07:00&#8230;<\/p>\n","protected":false},"author":1,"featured_media":185757,"comment_status":"closed","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"fifu_image_url":"https:\/\/cen.acs.org\/content\/dam\/cen\/104\/02\/09\/WEB\/AI-drug-discovery-company-Iambic-strikes-a-deal-with-Takeda---344651.jpg","fifu_image_alt":"","footnotes":""},"categories":[14],"tags":[],"class_list":["post-185756","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-artificial-intelligence"],"_links":{"self":[{"href":"https:\/\/testing.news-you-need.com\/index.php\/wp-json\/wp\/v2\/posts\/185756"}],"collection":[{"href":"https:\/\/testing.news-you-need.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/testing.news-you-need.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/testing.news-you-need.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/testing.news-you-need.com\/index.php\/wp-json\/wp\/v2\/comments?post=185756"}],"version-history":[{"count":1,"href":"https:\/\/testing.news-you-need.com\/index.php\/wp-json\/wp\/v2\/posts\/185756\/revisions"}],"predecessor-version":[{"id":185758,"href":"https:\/\/testing.news-you-need.com\/index.php\/wp-json\/wp\/v2\/posts\/185756\/revisions\/185758"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/testing.news-you-need.com\/index.php\/wp-json\/wp\/v2\/media\/185757"}],"wp:attachment":[{"href":"https:\/\/testing.news-you-need.com\/index.php\/wp-json\/wp\/v2\/media?parent=185756"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/testing.news-you-need.com\/index.php\/wp-json\/wp\/v2\/categories?post=185756"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/testing.news-you-need.com\/index.php\/wp-json\/wp\/v2\/tags?post=185756"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}